Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

N-methyl D-aspartate (NMDA) receptors are ligand-gated cation channels activated by glutamate, an excitatory neurotransmitter. These receptors are located mostly at excitatory synapses and, thereby, ...

The difference between mental health and mental illness can turn on changes in brain cells and their connections that are almost incomprehensibly tiny, at least in physical terms. This irony is ...

Glutamate receptors mediate most rapid excitatory neurotransmission in the CNS and are important in neuronal development, synaptic plasticity, and learning and memory. Glutamate receptors are highly ...

Recent evidence in vitro suggests that the tuft dendrites of pyramidal neurons are capable of evoking local NMDA receptor–dependent electrogenesis, so-called NMDA spikes. However, it has so far proved ...

"Most NMDA receptors are found in synapses, where they enhance neuronal connections. However, those located outside the synapse are more associated with processes of toxicity and cell death, which may ...

It remains difficult to distinguish anti-NMDA receptor encephalitis from a primary psychiatric disorder, but recent studies have identified clinical features and proposed screening criteria that could ...

Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...

Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...

One of several types of ligand-gated ion channel, the N-methyl-D-aspartate (NMDA) receptor transmits excitatory stimuli in the brain. When calcium flows through this channel, neural plasticity happens ...

In February 2025, Ryan Alto, a 48-year-old from California, developed what seemed like a routine flu. He had a headache, body aches, and general fatigue, but within hours of driving himself to the ...